About us | Advertise with us | Contact us


Posted: 1 December 2025 | Drug Target Review | No comments yet
A novel CAR-NKT immunotherapy developed at UCLA has shown striking success in preclinical models of metastatic pancreatic cancer, which could hopefully lead to more accessible treatments.
Pancreatic cancer is one of the most fatal malignancies, with most patients diagnosed only after the disease has already spread. For those with metastatic cancer, the five-year survival rate sits at just 2–3 percent, and median survival is typically measured in months. Now, a breakthrough study from researchers at UCLA could be a pivotal shift in treatment.
The study details a novel cell therapy, known as CAR-NKT cell therapy, which has demonstrated the ability to track and destroy pancreatic tumours even after they have metastasised to other organs. The researchers believe this approach may finally begin to overcome the disease’s longstanding resistance to treatment.
“Developing a therapy that targets both the primary tumour and its metastases in preclinical studies – one that can be ready to use off-the-shelf – represents a fundamental shift in how we might treat this disease,” said senior author Dr Lili Yang, professor of microbiology, immunology and molecular genetics at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.
 
access your free copy
 
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
 
Unlike personalised cell therapies that require weeks of bespoke manufacturing, CAR-NKT cell therapy is designed for mass production. The cells can be generated from donor blood stem cells, stored and delivered immediately when needed – and at a dramatically lower cost.
Each dose would cost around $5,000, compared with the hundreds of thousands associated with conventional personalised cell therapies. For many pancreatic cancer patients, who often cannot afford to wait weeks for treatment, this speed could be vital.
CAR-T therapies have achieved significant success in blood cancers, yet solid tumours like pancreatic cancer are far tougher to treat. Dense connective tissue and suppressive immune environments act as a blockade, and tumours frequently change their molecular markers to evade detection.
CAR-T therapies have achieved significant success in blood cancers, yet solid tumours like pancreatic cancer are far tougher to treat.
To tackle these barriers, the researchers turned to invariant natural killer T cells – or NKT cells – a rare immune cell type capable of mounting multiple attacks at once. By engineering these cells with a chimeric antigen receptor targeting mesothelin, the researchers created a therapy that can strike the tumour from several angles simultaneously.
“We’re essentially surrounding the tumour with no escape routes,” said first author Dr Yanruide Li, a postdoctoral scholar in the UCLA Broad Stem Cell Research Center Training Programme. “Even when the cancer tries to evade one attack pathway by changing its molecular signature, our therapy is hitting it from multiple other angles at the same time. The tumour simply can’t adapt fast enough.”
Microscopy image showing a stem cell-engineered CAR-NKT cell (blue) attacking a human solid tumor cell (magenta). Credit: Lili Yang Lab/UCLA
Metastatic tumours in the liver and lungs are notoriously difficult for immune therapies to reach. To try and overcome this, the researchers used advanced preclinical models that closely mimic human pancreatic cancer, including orthotopic tumours and metastatic liver lesions.
“Many treatments that looked promising in simpler lab models have completely failed in patients,” said study collaborator Dr Caius Radu. “The fact that this therapy worked in both settings is genuinely encouraging.”
The engineered cells displayed strong tumour-homing behaviour due to high levels of chemokine receptors. “When the tumour is in the lung, they go to the lung. When it’s in the pancreas, they go to the pancreas,” Li said.
The therapy also showed consistent effectiveness across multiple tumour models, maintaining potency in harsh tumour environments and showing minimal exhaustion – a common weakness in other cell therapies.
Now preclinical studies are complete; the team is preparing FDA applications to begin clinical trials.
Because mesothelin is also over-expressed in breast, ovarian and lung cancers, the approach could be extended well beyond pancreatic cancer. Now preclinical studies are complete; the team is preparing FDA applications to begin clinical trials.
“Pancreatic cancer patients need better treatment options now,” Yang said. “We’ve developed a therapy that’s potent, safe, scalable and affordable. The next critical step is proving it can deliver the same results in patients that we’ve seen in our preclinical work.”
Related topics
Antibody Discovery, Biologics, Biopharmaceuticals, Biotherapeutics, Cancer research, Cell Therapy, Cell-based assays, Clinical Trials, Drug Development, Drug Discovery, Immunotherapy, Oncology, Translational Science
Related conditions
Pancreatic cancer
Related organisations
UCLA
Related people
Dr Lili Yang (Professor at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA), Dr Yanruide Li (postdoctoral scholar in the UCLA Broad Stem Cell Research Center Training Programme.)
By Drug Target Review
1 December 2025
No comments yet
Antibody Discovery, Biologics, Biopharmaceuticals, Biotherapeutics, Cancer research, Cell Therapy, Cell-based assays, Clinical Trials, Drug Development, Drug Discovery, Immunotherapy, Oncology, Translational Science
Pancreatic cancer
UCLA
Dr Lili Yang (Professor at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA), Dr Yanruide Li (postdoctoral scholar in the UCLA Broad Stem Cell Research Center Training Programme.)
All subscriptions include online membership, giving you access to the journal and exclusive content.
By Eurofins Discovery
By Drug Target Review
By Drug Target Review
By Anja Harmeier (CEO of Rewind Therapeutics)
By Drug Target Review
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website

Write for us | Advertise with us
T: +44 (0)1959 563311
F: +44 (0)1959 563123

Drug Target Review is published by:
Russell Publishing Ltd.
Court Lodge
Hogtrough Hill
Brasted, Kent, TN16 1NU
United Kingdom
© Russell Publishing Limited, 2010-2025. All rights reserved. Terms & Conditions | Privacy Policy | Cookie Policy
Website development by e-Motive Media Limited.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as “Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies enable the core functionality of the website, including security, network management and accessibility. These cookies do not store any personal information. You may disable these by changing your browser settings, but this may affect how the website functions.

Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.

Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.

Performance cookies include cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.

source